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Nicotinic acetylcholine receptors (nAChRs) are pentameric,
neurotransmitter-gated ion channels responsible for rapid
excitatory neurotransmission in the central and peripheral
nervous systems, resulting in skeletal muscle tone and various
cognitive effects in the brain. These complex proteins are acti-
vated by the endogenous neurotransmitter ACh as well as by
nicotine and structurally related agonists. Activation and mod-
ulation of nAChRs has been implicated in the pathology of mul-
tiple neurological disorders, and as such, these proteins are
established therapeutic targets. Here we use unnatural amino
acid mutagenesis to examine the ligand binding mechanisms of
two homologous neuronal nAChRs: the44 and7 receptors.
Despite sequence identity among the residues that form the core
of the agonist-binding site, we find that the 44 and 7
nAChRs employ different agonist-receptor binding interactions
in this region. The 44 receptor utilizes a strong cation-
interaction to a conserved tryptophan (TrpB) of the receptor for
both ACh and nicotine, and nicotine participates in a strong
hydrogen bond with a backbone carbonyl contributed by TrpB.
Interestingly, we find that the 7 receptor also employs a cat-
ion- interaction for ligand recognition, but the site has moved
to a different aromatic amino acid of the agonist-binding site
depending on the agonist. ACh participates in a cation- inter-
actionwithTyrA,whereas epibatidine participates in a cation-
interaction with TyrC2.
Nicotinic acetylcholine receptors (nAChRs)2 belong to the
Cys loop superfamily of neurotransmitter-gated ion channels,
which also includes GABAA and GABAC, glycine, and sero-
tonin type 3 (5-HT3) receptors. These transmembrane proteins
are essential for proper rapid synaptic transmission in the cen-
tral and peripheral nervous systems (1). One or more nAChRs
are implicated in pathophysiology and/or therapy of multiple
neurological and psychiatric disorders including addiction,
schizophrenia, Parkinson disease, Alzheimer disease, pain,
attention deficit hyperactivity disorder, epilepsy, depression,
and congenital myasthenic syndromes (2, 3).
The nAChR is the longest known, most studied neurorecep-
tor. Early work established a nicotinic pharmacophore com-
prised of a cationic N and a hydrogen bond-accepting group
separated by an appropriate distance (4, 5). This pharmacoph-
ore is also present in the potent agonist epibatidine and in cyt-
isine, which has served as an important lead compound for
discovery of new nicotinic drugs (6). Although the overall lay-
out of the receptor has been delineated by cryo-electron
microscopy images of the Torpedo californica nAChR (7), the
present work focuses on the agonist-binding site. Ligands bind
at a subunit interface in the large, N-terminal, extracellular
domain. A major advance in the field was the discovery and
structural characterization of the family of snail acetylcholine-
binding proteins, which share 20–25% sequence identity with
the extracellular domain of the nAChR (8, 9). The cationicmoi-
ety of ACh interacts with a cluster of aromatic amino acids.
These aromatic residues were first identified by photoaffinity
labeling and mutagenesis experiments of the full receptor and
subsequently located by the acetylcholine-binding protein crys-
tal structures (1, 8). The binding site “aromatic box” is formed
by five residues: four contributed by the “principal” subunit
(TyrA, TrpB, TyrC1, and TyrC2) and one contributed from the
“complementary” surface or subunit (TrpD), and these five aro-
matics are completely conserved within the nAChR family (Fig.
1). The hydrogen bond acceptor of the agonist interacts with
residues from the complementary subunits ( in neuronal
nAChRs and , , and  in the muscle-type nAChR) (10).
To date, 16 mammalian genes have been identified that
encode nAChR subunits, termed 1–7, 9, 10, 1–4, , ,
and . Themuscle-type nAChR, post-synaptically located at the
neuromuscular junction, has a uniquely precise stoichiometry
of (1)21 (fetal form; the adult form is (1)21). Most
other nAChRs are located post- or pre-synaptically in auto-
nomic ganglia and cholinergic neurons throughout the central
nervous system; some of the so-called “neuronal” nAChRs,
such as the 7 subtype studied in this paper, also occur on
non-neuronal cells (2,11). Neuronal nAChRs have variable sto-
ichiometries formed fromvarious combinations of and sub-
units (11). This large collection of closely related receptors—
current estimates are that as many as 25 nAChR subtypes are
active in humans—presents special challenges to drug discov-
ery efforts (3). It seems certain that therapeutics directed
toward specific neurological disorders will require selectivity in
terms of which nAChR subtype(s) is targeted.
In previous work, we have studied the muscle-type and neu-
ronal 42 receptors (12–15). Here we extend our studies of
the principal component of the agonist-binding site to two
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other subtypes of the nAChR family, the neuronal 44 and 7
receptors. The 4 and 4 subunits colocalize in brain regions
implicated in behavioral responses to nicotine, such as the
medial habenula (2, 16). The 4 subunit is more commonly
expressedwith the3 subunit, where it forms themajor nAChR
of autonomic ganglia, and a cluster of genes including the 4,
3, and 5 subunits are repeatedly identified in genome wide
association studies and candidate gene studies that focus on
nicotine dependence (2, 17). It is not yet known whether these
associations arise from peripheral or central nervous system
nAChRs. Further supporting the role of the 4 subunit in acute
responses to nicotine, 4/ knock-out mice are more resis-
tant to nicotine-induced seizures when compared with wild
type mice (2). The pharmacology of the 44 nAChR differs
markedly from that of the muscle-type and 42 receptors,
providing a valuable comparison for the structure-function
studies employed here.
The homopentameric7nAChR is one of themost prevalent
neuronal nAChR subtypes and is a potential therapeutic target
in schizophrenia, Alzheimer disease, and inflammation (18–
20). These receptors are richly expressed in most forebrain,
midbrain, and hindbrain regions, as well as in some non-neu-
ronal cells (2, 21). Brain expression is heaviest in the neonatal
period, when the endogenous ligand may be choline; even in
adults, most neurons exhibit ACh responses with characteristic
7 waveforms and pharmacology (22–24). In neurons and het-
erologous expression systems, 7 nAChRs exhibit responses
that desensitize within 10–100 ms (25), but even the peak 7
responses are less sensitive to agonists than are 42 or 44
responses (2, 26). Despite the widespread expression of the 7
nAChR, homozygous7 knock-outmice are viable (27).Mouse
strains with low expression of 7 nAChRs provide a useful
model for schizophrenia (28, 29), and 7 nAChRs may be acti-
vated by the high concentrations of nicotine that are produced
by the heavy smoking habits of many schizophrenics (30, 31).
Herewe use unnatural amino acidmutagenesis to investigate
the ligand bindingmodes of the neuronal44 and7 nAChRs
(Fig. 2). In the 44 receptor, we establish a strong cation-
interaction to a conserved tryptophan (TrpB) of the receptor
for both ACh and nicotine. Nicotine also participates in a
strong hydrogen bond with the backbone carbonyl contributed
by TrpB. Overall, the binding patterns are similar to that
reported for the 42 receptor (15). The 7 receptor also
employs a cation- interaction for ligand recognition, but sur-
prisingly, we find that the locus has moved to a different aro-
matic amino acid of the agonist-binding site depending on the
agonist. ACh participates in a cation- interaction with TyrA,
whereas the nicotine analog epibatidine participates in a cat-
ion- interaction with TyrC2.
EXPERIMENTAL PROCEDURES
Molecular Biology—nAChR subunits of human 4 and 4
were in pGEMhe, whereas rat 7 was in pAMV. Site-directed
mutagenesis was performed using the QuikChange protocol
(Stratagene). For nonsense suppression experiments, the site of
interest within the nAChR subunit was mutated to an amber
stop codon. Circular DNA for 4 and 4 was linearized with
NheI. Circular 7 DNA was linearized with NotI. After purifi-
cation (Qiagen), linearized DNA was used as a template for
runoff in vitro transcription using T7mMessage mMachine kit
(Ambion). hRIC-3 cDNA in pGEM was obtained from Dr.
MillerTreinin atHebrewUniversity. Circular hRIC-3DNAwas
linearized with XhoI, and mRNA was prepared as previously
described.
THG73 (32) was used as the amber suppressor tRNA. The
nitroveratryloxycarbonyl-protected cyanomethyl ester form of
FIGURE 1.nAChR structure. Left panel, global layout of the nAChR based on cryo-electronmicroscopy of the Torpedo receptor (Protein Data Bank code 2BG9)
(7). The position of the membrane is denoted by gray bars. A large intracellular domain that is only partly observed in the structure is omitted. Right panel,
enlargement of agonist-binding site from acetylcholine-binding protein (Protein Data Bank code 1I9B) (8). Aromatic residues forming the ligand-binding site
are indicated. Note that TyrA, TrpB, TyrC1, and TyrC2 are contributed by the  subunit, whereas TrpD is contributed by the non- subunit. Coloring of the
residue labels matches that of the corresponding loops in the full structure. Backbone carbonyl contributed by TrpB is denoted by a star.
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unnatural amino acids and -hydroxythreonine cyanomethyl
ester were synthesized, coupled to dinucleotide dCA, and enzy-
matically ligated to 74-nucleotide THG73 tRNACUA as previ-
ously reported (33). Crude tRNA amino acid product was used
without desalting, and the product was confirmed by MALDI-
TOF MS on 3-hydropicolinic acid matrix. Deprotection of the
nitroveratryloxycarbonyl group on the tRNA-amino acid was
carried out by photolysis for 5 min prior to co-injection with
mRNA containing the UAG mutation at the site of interest.
Microinjection—Stage V–VI Xenopus laevis oocytes were
employed. Co-injection of4:4mRNAat a ratio of 1:1 bymass
or lower yielded wild type (4)2(4)3 receptors, whereas a ratio
of 30:1 by mass or higher produced pure populations of
(4)3(4)2. If an unnatural amino acid was to be incorporated
into the 4 subunit to produce a (4)2(4)3 receptor, then a
mass ratio of 2:1 for4:4mRNAwas injected into each oocyte.
For 44 experiments, the total mRNA injected was 25–65
ng/oocyte depending on the relative expression level. For 7
T6S experiments, 10–25 ng of7T6SmRNAwas co-injected
with 20 ng of hRIC-3 mRNA per oocyte. For all of the suppres-
sion experiments, 15 ng of tRNA/cell was used. Each oocyte
was injected with 50 nl of RNA solution, and the oocytes were
incubated for 24–48 h at 18 C in culturemedium (ND96with
2.5% horse serum). In the case of low expressing mutant recep-
tors, a second injection was required 24 h after the first injec-
tion. As a negative control for all suppression experiments,
76-nucleotide tRNA (dCA ligated to 74-nucleotide tRNA) was
co-injected with mRNA in the same manner as fully charged
tRNA.
Electrophysiology—Acetylcholine chloride and ()-nicotine
tartrate were purchased from Sigma/Aldrich/RBI, and drug
dilutions were prepared from 1 M aq stock solutions. ()-Epi-
batidine was purchased from Tocris, and drug dilutions were
prepared from a 50 mM stock solution (1:1 H2O:EtOH). For
44 experiments, drug dilutions were prepared in calcium-
freeND96buffer. For7T6S experiments, drug dilutionswere
prepared in calcium-containing ND96 buffer.
Ion channel function was assayed using the OpusXpress
6000A (MolecularDevicesAxon Instruments) in two-electrode
voltage clamp mode. The oocytes were clamped at a holding
FIGURE 2. Key structures employed in this study. A, structures of ACh, nicotine, and epibatidine. B, unnatural amino acids used in the present study. If not
indicated, a, b, c, or d group is H. C, -hydroxy acid incorporation; the backbone ester strategy for modulating a hydrogen bond. F-Trp, 5-fluoro-tryptophan;
F2-Trp, 5,7-difluoro-tryptophan; F3-Trp, 5,6,7-trifluoro-tryptophan; F4-Trp, 4,5,6,7-tetrafluoro-tryptophan; 5-Br-Trp, 5-bromo-tryptophan; 7-aza-Trp, 7-aza-tryp-
tophan; F1-Phe, 4-flouro-phenylalanine; F2-Phe, 3,5-diflouro-phenylalanine; F3-Phe, 3,4,5-triflouro-phenylalanine; 4-Br-Phe, 4-bromo-phenylalanine; 4-CN-Phe,
4-cyano-phenylalanine; 3-MeO-Phe, 3-methoxy-phenylalanine; 4-Me-Phe, 4-methyl-phenylalanine; 4-Ac-Phe, 4-acetyl-phenylalanine; 4-COOH-Phe, 4-carboxy-
phenylalanine;mTyr,meta-tyrosine.
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potential of 60 mV. For 44 receptors, 1 ml of each drug
solution was applied to the clamped oocytes for 12 s and fol-
lowed by a 2-min wash with calcium-free ND96 buffer between
each concentration. For 7 T6S receptors, 1 ml of each drug
solution was applied for 30 or 12 s, followed by a 5-min wash
step with calcium-containing ND96 buffer between each con-
centration. The data were sampled at 125 Hz and filtered at
50 Hz.
Data Analysis—Dose-response data were obtained for at
least six concentrations of agonists and for a minimum of five
oocytes (from two different batches). Mutants with Imax of at
least 100 nA of current were defined as functional. The EC50
and Hill coefficient (nH) values were calculated by fitting the
averaged, normalized dose-response relation to the Hill equa-
tion. All of the data are reported as the means S.E.
RESULTS
Challenges in Studying Neuronal nAChRs with Unnatural
Amino Acids—The nonsense suppression methodology for
incorporating unnatural amino acids into receptors and ion
channels expressed in Xenopus oocytes has proven to be
broadly applicable, including studies of serotonin (5-HT3)
receptors, GABA receptors, glycine receptors, K and Na
channels, and G protein-coupled receptors such as the D2
dopamine and M2 muscarinic ACh receptors (13, 33–37).
Studies of the muscle-type nAChR have long been straightfor-
ward, but attempts to apply the methodology to neuronal
nAChRswere initially frustrated by several factors. These issues
include poor expression in Xenopus oocytes and some intrinsic
pharmacological properties of the receptors. Here, we report
the strategies used to overcome these obstacles in both the
44 and 7 receptors.
First, expression of the nAChRs in Xenopus oocytes yields
variable stoichiometries. This can be problematic, because
interpretation of subtle structure-function studies requires a
homogeneous collection of receptors. Several studies of other
receptor subtypes have shown that biasing the ratios of subunit
mRNAs injected into the oocyte can influence subunit stoichi-
ometry (15, 38), and we have found similar results in our previ-
ous studies of unnatural amino acids in the 42 receptor (15).
For the 42 nAChR, the (4)2(2)3 form is the higher sensi-
tivity form for nicotine, and chronic exposure to nicotine leads
to up-regulation of this form at the expense of (4)3(2)2 in a
variety of cell types (38, 39).
In initial studies of the 44 receptor, we observed variable
dose-response curves and anomalously low Hill coefficients,
indicating a mixed population of receptors. By biasing the
subunit mRNA ratios, we observed two dominant 44 recep-
tor populations, which we have assigned as (4)2(4)3 and
(4)3(4)2. To facilitate comparisons and to emphasize the crit-
ical role of the subunit in defining drug selectivity at nAChRs,
our studies of the 44 nAChR have focused on the (4)2(4)3
form.We found that injection of anmRNA ratio4:4 of 1:1 or
lower produces a pure population of (4)2(4)3, whereas a ratio
of 30:1 or higher is necessary to produce pure populations of
(4)3(4)2 (supplemental Table S1).
Studies of the homopentameric 7 nAChR also presented
several challenges, including poor expression and agonist con-
centration-dependent desensitization; the latter impedes accu-
ratemeasurement of dose-response relations. To overcome the
issue of poor expression, we co-expressed the 7 nAChR with
the human homolog of the RIC-3 protein (hRIC-3). Other stud-
ies have shown that co-expression with hRIC-3 enhances sur-
face expression of 7 nAChRs, presumably by aiding the fold-
ing, assembly, and/or trafficking of the 7 protein (40–44).
Regarding desensitization, we introduced a mutation into the
M2 transmembrane helix, termed T6S. Previous work estab-
lished that this mutation, which lies 60 Å from the agonist-
binding site, decreases desensitizationwithout disrupting other
aspects of receptor pharmacology (45). All of the studies of the
7 receptor reported here include this mutation.
Nicotine is not a potent agonist for 7 receptors; this com-
plicates analyses ofmutant receptors with elevated EC50 values.
On the other hand, the important natural product and close
nicotine analog epibatidine is a potent agonist at 7 nAChRs
(Table 1). In addition, we have shown that epibatidine partici-
pates in the same kinds of interactions with specific residues as
nicotine does in receptors at which nicotine is potent (10, 14).
TABLE 1
EC50 values (M) for mutant (4)2(4)3 and 7 nAChRs
The EC50 values are S.E. NR, no response; ND, not determined; F1-Trp, 5-fluoro-
tryptophan; F2-Trp, 5,7-difluoro-tryptophan; F3-Trp, 5,6,7-trifluoro-tryptophan;
F4-Trp, 4,5,6,7-tetrafluoro-tryptophan; 5-Br-Trp, 5-bromo-tryptophan; 7-aza-Trp,
7-aza-tryptophan; F1-Phe, 4-flouro-phenylalanine; F2-Phe, 3,5-diflouro-phenylala-
nine; F3-Phe, 3,4,5-triflouro-phenylalanine; 4-Br-Phe, 4-bromo-phenylalanine;
4-CN-Phe, 4-cyano-phenylalanine; 3-MeO-Phe, 3-methoxy-phenylalanine; 4-Me-
Phe, 4-methyl-phenylalanine; 4-Ac-Phe, 4-acetyl-phenylalanine; 4-COOH-Phe,
4-carboxy-phenylalanine; Cha, cyclohexylalanine; Tah, threonine--hydroxy.
44 7
ACh Nicotine ACh Epibatidine
Wild type 13 1 2.4 0.1 94 3 0.34 0.01
TyrA
Tyr 17 1 3.1 0.2 93 10 0.38 0.05
Phe 260 11 11 0.4 4500 200 3.0 0.04
F1-Phe 254 21 6.6 0.6 1400 100 3.0 0.1
F2-Phe 159 16 7.1 0.4 4100 200 18 1
F3-Phe 158 14 7.7 0.5 6000 200 15 2
4-Br-Phe 49 1 3.5 0.2 78 3 0.34 0.04
4-CN-Phe 855 63 80 6 1700 100 1.8 0.2
4-MeO-Phe 50 2 4.2 0.2 103 3 0.94 0.09
TrpB
Trp 15 1 2.0 0.1 93 9 0.38 0.02
F1-Trp 41 2 5.6 0.5 ND ND
F2-Trp 51 2 8.1 0.9 87 5 0.62 0.04
F3-Trp NR 73 6 ND ND
F4-Trp NR 190 116 ND ND
5-Br-Trp 28 1 7.1 0.5 ND ND
5-CN-Trp 254 27 46 3 63 4 0.14 0.03
7-aza-Trp 162 17 28 2 ND ND
TyrC1
Tyr 11 1 1.8 0.1 98 5 ND
Phe 1100 126 60 2 8600 600 ND
4-Br-Phe 1400 140 65 9 ND ND
4-CN-Phe 2700 500 156 13 ND ND
4-MeO-Phe 550 37 75 9 NR ND
TyrC2
Tyr 11 1 2.2 0.1 94 2 0.35 0.04
Phe 26 1 2.0 0.2 560 20 3.8 0.4
F1-Phe ND ND 86 5 1.1 0.02
F2-Phe ND ND 870 40 13 1
F3-Phe ND ND 1300 100 16 1
4-Br-Phe 4.5 0.3 0.36 0.01 51 2 0.32 0.02
4-CN-Phe 11 1 2.5 0.1 150 10 2.1 0.04
4-MeO-Phe 13 1 1.3 0.1 160 10 0.41 0.01
Trp(B1)
Thr 15 1 1.7 0.1 47 2 0.45 0.01
Tah 12 1 23 1 11 1 0.95 0.03
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As such, our studies of the 7 nAChR have used epibatidine
along with ACh.
With the above strategies, unnatural amino acidmutagenesis
studies of the 44 and 7 receptors proceeded smoothly (Fig.
3). In the present work, we report EC50 values, which indicate a
functional measure that can be altered by changes in agonist
affinity and/or receptor gating. All of our previous studies of the
aromatic box of nAChRs have employed this metric, and so
using EC50 measurements allows direct comparisons between
different subtypes. In addition, an earlier study of the 42
receptor employed single-channel analysis to establish that
shifts in EC50 caused by subtlemutations at TrpB, amajor focus
of the present work, result from changes in agonist affinity, not
receptor gating (15).
Ligand Binding Mechanism of the 44 Receptor—Our lab
has previously established that the muscle-type and 42
nAChRs interactwith agonists through cation- interactions at
TrpB (12, 15).We therefore focused onTrpB in the44 recep-
tor using strategies that are nowwell established for identifying
a cation- interaction. In particular, we systematically fluori-
nate a side chain and determine whether the progressive dimi-
nution of the cation- binding ability of the residue induced by
fluorination is manifested in receptor function. The fluorina-
tion approach can be augmented with other substitutions, such
as the highly deactivating cyano (CN) substituent, which is
compared with themuch less deactivating but sterically similar
bromo substituent. With ACh as the agonist, both the 5-CN-
Trp/5-bromo-tryptophan effect (9-fold ratio of EC50; Table 1
and supplemental Table S2) and the fluorination effect (Fig. 4A)
establish that a cation- interaction is present at TrpB. Efforts
to incorporate 5,6,7-trifluoro-tryptophan or 4,5,6,7-tetra-
fluoro-tryptophan gave low expression yields, such that we
were unable to achieve large enough signals with ACh as ago-
nist but could do sowith nicotine as agonist. To compensate for
the lack of ACh data, we incorporated 7-aza-tryptophan, which
is structurally very similar to Trp but shows a diminished cat-
ion- binding ability. When all the data are combined (Trp,
5-fluoro-tryptophan, 5,7-difluoro-tryptophan, 7-aza-trypto-
phan, 5-bromo-tryptophan, and 5-CN-Trp) into one plot, we
observe a linear correlation with ab initio calculated cation-
binding energies. The slope of this “fluorination plot” resembles
that reported for other nAChRs. A much more thorough study
was possible with nicotine as the agonist, producing compelling
evidence for a cation- interaction to TrpB (Fig. 4B). Interest-
ingly, when considering the effects of nicotine at TrpB, the cat-
ion- slope resembles that of the42 receptor rather than the
muscle-type receptor, which shows no consistent fluorination
effect with nicotine as the agonist. Hence, in the44 receptor,
similar to the42 receptor (15), nicotinemimics ACh at TrpB
with regard to the cation- interaction.
We performed extensive studies of the remaining compo-
nents of the aromatic box contributed by the principal face of
the ligand-binding domain (TyrA, TyrC1, and TyrC2). Histor-
ically, nonsense suppression with tyrosine derivatives has
provenmore challenging than tryptophanderivativeswhen one
probes for a cation- interaction. Direct fluorination of tyro-
sine progressively lowers the pKa of the side chain hydroxyl
group, such that the pKa for tetrafluorotyrosine is 5.3 (low-
ered from 10 for tyrosine). This decrease in pKa can lead to
ionization of the hydroxyl in unnatural tyrosine analogs. Thus,
observed shifts in EC50 could result from ionization of the
hydroxyl group rather than changes in the cation- binding
ability, complicating analysis. In other receptors, we have cir-
cumvented this potential problem by first incorporating phe-
nylalanine, followed by successively fluorinated phenylalanine
derivatives, which avoids pKa complications (46).
In the 44 receptor, we found that for TyrA deletion of the
hydroxyl group (to give Phe) negatively impacts receptor func-
FIGURE 3.Wild type recovery experiments. A, 44 nAChR; representative voltage-clamp current traces from oocytes with Trp incorporated by nonsense
suppression at position TrpB. B, 7 nAChR; representative voltage-clamp current traces from oocytes with Tyr incorporated by nonsense suppression at
position TyrC2. InA and B, bars indicate applicationof ACh (inM) at concentrations noted.C, dose-response curve and fit of data inA and B to theHill equation.
The error bars indicate S.E. (n 10–13).
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tion for both ACh and nicotine (Table 1). Interestingly, incor-
poration of either 4-MeO-Phe or 4-bromo-phenylalanine
perturbs receptor functionmuch less, whereas 4-cyano-pheny-
lalanine is strongly perturbing. This represents a distinction in
the behavior of TyrA when comparing 44 to the 42 and
muscle-type receptors. For proper receptor function in the
44 receptor, it appears that TyrA requires only steric bulk at
this position. However, 4-MeO-Phe is highly deleterious in the
42 and muscle-type receptors, suggesting that a hydrogen
bond donor is required. Successive fluorination of phenylala-
nine does not result in progressively reduced channel function;
we conclude that neither ACh nor nicotine participates in a
cation- interaction with TyrA.
The remaining two residues, TyrC1 andTyrC2, are both con-
tributed by loop C, a verymobile component of the binding site
(47). We probed both of these residues for possible hydrogen
bonding and cation- interactions, and we find that TyrC1 and
TyrC2 display opposite effects. TyrC1 is highly sensitive to any
mutation that obliterates the hydrogen bond donating ability,
as evidenced by a rightward shift in EC50 of over 50-fold
for ACh and 30-fold for nicotine in response to the Phe,
4-MeO-Phe, 4-bromo-phenylalanine, and 4-cyano-phenylala-
nine mutations (Table 1). This is a phenotype we have seen at
TyrC1 for all the nAChRswehave studied, andwe interpret it to
indicate that the OH of TyrC1 contributes a hydrogen bond
that is critical to receptor function. If this position served as a
hydrogen bond acceptor, then incorporation of 4-MeO-Phe
would have rescued normal channel function. Rather, incorpo-
ration of 4-MeO-Phe resulted in substantial loss of channel
function; therefore, we conclude that TyrC1 is an important
hydrogen bond donor.
In contrast, TyrC2 is quite receptive to mutations of the
4-position hydroxyl group, with many types of substituents
accepted and no obvious structure-function relationship. The
fact that 4-cyano-phenylalanine gives essentially wild type
behavior for both ACh and nicotine would appear to rule out a
strong cation- interaction at this site. These results suggest
that TyrC2 participates structurally in shaping the ligand-bind-
ing site rather than directly in ligand recognition. Again, the
results for both TyrC1 and TyrC2 are similar to what is seen for
muscle-type and 42.
In 44, we also investigated the hydrogen bonding capabil-
ity of the backbone carbonyl of TrpB (Fig. 1), because this site is
known to behave differently in the muscle-type and 42
nAChRs (14, 15). By replacing the amino acid at the i 1 posi-
tion with the analogous -hydroxy acid, one converts the car-
bonyl associated with residue i to an ester carbonyl rather than
an amide (peptide) carbonyl (Fig. 2C) (14). It is well established
that ester carbonyls are poorer hydrogen bond acceptors than
amide carbonyls, and so if a hydrogen bond to this carbonyl is
essential, the backbone estermutation should influence agonist
potency.With nicotine as the agonist, the backbone estermuta-
FIGURE 4. Cation- binding plots, in which log[EC50(mut)/EC50(wt)] is
plotted versus quantitative cation- binding energies (12, 35). The data
are from Table 1. Where not visible, the error bars are smaller than the data
marker. A and B, cation- plots for 44 nAChR at position TrpB with ACh (A)
and nicotine (B). C and D, cation- plots for 7 nAChR at position TyrA with
ACh (C) and epibatidine (D). E, position TyrC2 with epibatidine.
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tion causes a 14-fold increase in EC50 in44 (Table 1). Impor-
tantly, the potency of ACh, which cannot make a conventional
hydrogen bond to the carbonyl, is essentially unperturbed by
the backbone ester mutation. This establishes that the muta-
tion does not globally alter the binding/gating characteristics of
the receptor, supporting the notion that we are modulating a
hydrogen bonding interaction between the receptor and nico-
tine. As with TrpB, the behavior of 44 is more similar to that
of 42 rather than muscle-type.
The 7 Receptor Reveals a Different Ligand Binding Mode—
Quite surprisingly, in the 7 nAChR, TrpB does not make a
cation- interaction with either ACh or epibatidine as agonist.
Incorporation of both 5-CN-Trp and 5,7-difluoro-tryptophan
produced functional receptors with essentially wild type behav-
ior (Table 1). Nicotine cannot be systematically studied at the
7 receptor, but we were able to obtain convincing qualitative
evidence that EC50 is also unperturbed by the 5-CN-Trp
mutant with nicotine as the agonist (48).
In other members of the Cys loop family, aromatics other
than TrpB make cation- interactions to their respective ago-
nists. In particular, both TyrA and TyrC2 have been shown to
participate in cation- interactions in select receptors (34, 36).
As such, we probed these residues in the 7 receptor.
We noted above that we typically use Phe as a starting point
for studies of a Tyr residue to avoid complications associated
with the pKa of the Tyr hydroxyl group. However, Phe is a
substantial loss-of-function mutation here. The data suggest
that having any substituent at all is preferable to nothing; for
example, 4-MeO-Phe is much more nearly wild type. As such,
we did not include 3,5-diflouro-phenylalanine, which lacks a
substituent in the 4-position, in the cation- plots.
Considering first TyrA of the 7 receptor, the effect of a
4-substituent is especially pronounced, with the Phe mutant
significantly compromised (48-fold for ACh) (Table 1). How-
ever, we find that 4-MeO-Phe, 4-bromo-phenylalanine,
4-acetyl-phenylalanine, and, to a lesser extent, 4-methyl-phe-
nylalanine rescued the wild type EC50 (supplemental Table S3).
It thus appears that in the 7 nAChR, some substituent is
required at the 4-position for proper receptor function. Con-
firming this observation, when themethoxy or hydroxyl groups
are moved to the meta position (3-methoxy-phenylalanine and
meta-Tyr), receptor function is greatly compromised (supple-
mental Table S3). In this regard, the behavior of this TyrA is
similar to that observed for the44 receptor, but not the42
or muscle-type receptors, for which the OH appears to be a
hydrogen bond donor, not a steric placeholder.
We also gathered data suggesting that in the 7 receptor,
TyrA interacts with ACh through a cation- interaction (Fig.
4C). We can anticipate more scatter in this 7 cation- plot
than is typically seen, because the strong steric effect at the
4-position is overlaid on any electronic effect. For this reason,
we have not included especially the bulky bromo substituent.
When log(EC50) is plotted versus cation- binding ability for
residues designed to probe a cation- interaction, a clear cor-
relation is seen. Note also that although the fit to the line is not
as good aswe typically see, the slope is verymuch in the range of
what we observe for cation- interactions. Thus, we feel the
most reasonable interpretation of the data is that there is a
cation- interaction betweenAChandTyrA in the7 receptor.
In contrast to the results for ACh, when epibatidine is used as
agonist, the TyrA plot shows more scatter and a smaller slope
(Fig. 4D). It appears that there may be a cation- interaction
present, but if so, it appears to be weaker than normal.
We next considered TyrC2, and, similar to TyrA, the 4-sub-
stituent acts as a steric place holder for both ACh and epiba-
tidine. TyrC2 does not interact with ACh through a cation-
interaction (Table 1), as evidenced by the fact that 4-cyano-
phenylalanine gives near wild type behavior. However, with
epibatidine as the agonist, we observe a clear correlation in the
fluorination plot at TyrC2, with a larger slope than seen at TyrA
and less scatter (Fig. 4E). We conclude there is a significant
cation- interaction to TyrC2 for epibatidine but not for ACh.
We also explored the functional role of TyrC1 in the 7
receptor. As observed with other nAChRs, this site follows the
trend of being highly sensitive to mutation of the 4-position
hydroxyl group. Deletion of the hydroxyl group essentially
obliterated receptor function as shown by a 90-fold increase in
EC50, and incorporation of 4-MeO-Phe, F-Phe, and 3,4,5-tri-
flouro-phenylalanine did not yield functional receptors. We
also probed other aromatic residues near the aromatic binding
box; no compelling effects were observed for these residues
(supplemental Table S3).
We then evaluated the potential hydrogen bond to the back-
bone carbonyl of TrpB at position Ser-150 in the 7 receptor.
For these experiments, we employed the threonine/threonine-
-hydroxy pair, which is the same -hydroxy acid pair used in
44, 42, and muscle-type. Table 1 shows that the effect of
the Ser-to-Thr mutation is minimal. For 7, the results differ
markedly from those observed for 44 and 42. For epiba-
tidine, the backbone ester substitution minimally raises EC50,
but only 2.1-fold (Table 1), whereas for ACh the backbone ester
mutation lowers EC50 4-fold. This pattern is very similar to
that seen in the muscle-type receptor (14).
DISCUSSION
With 20 nAChR subtypes, these essential neurotransmit-
ter-gated ion channels provide a wide array of targets for
pharmaceutical development (1, 2). Given the considerable
sequence similarity, especially in the region of the agonist-bind-
ing site, it becomes quite challenging to discern the mecha-
nisms for differential activation of homologous receptors.Here,
we employ unnatural amino acid mutagenesis to address such
questions. This method enables subtle and systematic modifi-
cations that can isolate specific binding interactions and pro-
vide qualitative guidance on the relative magnitudes of specific
interactions.
The primary goal of the present work was to evaluate contri-
butions of the principal binding components of the aromatic
box to ligand binding in two neuronal nAChRs: the 44 and
7 receptors. Note that the side chains within the aromatic box
are identical in all the receptors considered: three tyrosines and
two tryptophans. Thus, differences among the receptors must
result from subtle structural effects.
Considering the44 receptor, the binding of ACh is similar
to what has previously been observed for the muscle-type and
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42 receptors. The quaternary ammonium ion of AChmakes
a cation- interaction to the face of the aromatic residue TrpB,
providing an unambiguous anchor point for ACh docking. The
slopes of the fluorination plots are as follows: 0.095, 0.100, and
0.095 for the 44, 42, and muscle-type nAChRs, respec-
tively (12, 15).We interpret such similarity in slopes to indicate
that the three receptors participate in equally strong cation-
interactions between ACh and TrpB. Further, we find that the
roles of the other residues of the aromatic box (TyrA, TyrC1,
and TyrC2) are similar to those seen in the muscle-type and
42 receptors when binding ACh.
An interesting result is observedwhennicotine is the agonist;
the neuronal 44 receptor acts similarly to the 42 receptor
rather than to the muscle-type receptor. In 44, nicotine
makes the same cation- interaction to TrpB as ACh, consis-
tent with the long-accepted nicotinic pharmacophore, but an
interaction that is absent in the muscle-type receptor. Interest-
ingly, the slope of the fluorination plot for 44 is 0.11, which
could suggest amoderately stronger cation- interaction at this
position than observed for 42 (slope  0.089) (15). Thus, a
cation- interaction to TrpB serves as a discriminator between
receptors with higher sensitivity to nicotine (44 and 42)
and those with lower sensitivity (muscle-type).
Furthermore, 44 also behaves like 42, not muscle-type,
concerning the hydrogen bond to the backbone carbonyl asso-
ciated with TrpB. At 44, nicotine displays a 14-fold decrease
in receptor function in response to the backbone ester muta-
tion, comparable with 19-fold for 42 and contrasting the
value of 1.6-fold for themuscle-type receptor (14, 15).Note that
when the agonist is ACh, a molecule unable to make a conven-
tional hydrogen bond to a carbonyl, essentially wild type recep-
tor behavior is observed. This indicates that the backbone
mutation did not alter receptor function downstream from
binding, i.e. gating.We conclude that nicotine is able to make a
hydrogen bond to the carbonyl in question in all three receptors
considered, but that the interaction is much stronger in the
neuronal 44 and 42 receptors. This is an additional con-
tributor to the enhanced potency of nicotine at the neuronal
44 and 42 receptors. Previous studies of neuronal
nAChRs have indicated that large differences in agonist affinity
are primarily determined by the nature of the complementary
subunit (49). Our results provide a molecular rationale indicat-
ing that both 4-containing neuronal receptors make the same
ligand-receptor interactions, but the magnitudes of the two
interactions examined differ depending on the receptor,
reflecting the nature of the  subunit. The cation- interaction
is stronger in the 44 receptor, whereas the hydrogen bond
interaction is stronger in the 42 nAChR.
We also examined the ligand-binding mechanism of a sec-
ond neuronal nAChR, the homopentameric 7 receptor. This
receptor, an interesting drug target, represents the third  sub-
unit we have probed, and it is novel because the complementary
component of the agonist-binding site is also defined by an 
subunit. Also, the7 receptor shows a generically lower affinity
than the other neuronal receptors we have considered, and it is
interesting to consider whether that behavior is reflected in the
aromatic box.
Remarkably, we find that the 7 receptor exhibits a dramat-
ically different binding mode when compared with all of the
other nAChRs studied. A strong cation- interaction toTrpB is
seen for ACh at muscle-type, 44, and 42 and for nicotine
at 42 and 44, but it is completely absent in 7. This result
is quite unambiguous; substitution of the native tryptophan
with 5-CN-Trp and 5,7-difluoro-tryptophan has no effect on
EC50 for ACh and the nicotine analog epibatidine. So, despite
complete sequence conservation among the five residues that
form the aromatic box, ACh adopts two different binding
modes in the neuronal nAChRs. To date, every Cys loop recep-
tor we have investigatedmakes a cation- interaction (50), so it
was not surprising to find one in the 7 receptor. For ACh as
agonist, that cation- site has moved to TyrA. Incorporation
of fluorinated phenylalanine derivatives produced a strong,
monotonic effect at this site, and although there are steric com-
plications associated withmodulating this tyrosine site, the lin-
ear correlation of the fluorination plot is good. The large
CN/bromo ratio further supports the existence of a cation-
interaction between ACh and TyrA for the 7 receptor.
Interestingly, when examining the effects of epibatidine at
TyrA of the 7 receptor (recalling that nicotine is not a viable
agonist at 7), the results are more complicated and, to some
extent, unprecedented. It is clear that fluorination at TyrA
impacts epibatidine potency, and more fluorines have a gener-
ally monotonic effect. However, the linear correlation is not as
compelling as previously observed in other systems. We inter-
pret the decreased slope for this fluorination plot to indicate a
weaker than usual cation- interaction. It is likely that a weaker
cation- interaction would make the fluorination plot more
susceptible to other variations such as steric effects, possibly
accounting for the poorer quality of the fit.
When studying epibatidine at TyrC2, a more compelling flu-
orination plot is obtained,with a better fit and a slopewithin the
normal range of previously reported cation- interactions.
Thus, it appears that epibatidine simultaneously interacts via a
cation- interaction with two residues of the aromatic box:
strongly with TyrC2 and moderately with TyrA. Although this
marks the first time we have observed such behavior in a Cys
loop receptor, it is quite plausible because these two tyrosines
are positioned near each other (Fig. 1), and epibatidine is large
enough to contact both residues simultaneously. In addition,
the protein structural data bank containsmany examples of two
aromatics making a strong cation- interaction to a single cat-
ion (51). Note that the energetic falloff of the cation- interac-
tion with distance between the cation and the aromatic is not
especially steep (52), and so even a cation that is not in direct
van der Waals contact with an aromatic residue experiences a
significant stabilization.
The 7 receptor also differs from the other neuronal recep-
tors with regard to the backbone hydrogen bond to the TrpB
carbonyl. The strong interaction to the TrpB backbone car-
bonyl seen in higher affinity receptors (44 and 42) is
greatly diminished in 7. In fact, with regard to the hydrogen
bonding seenwith nicotinic-type agonists (but not the cation-
interaction), the 7 receptor is qualitatively similar to the mus-
cle-type receptor. Additionally, both have comparatively low
sensitivity for the two ligands tested. Both the muscle-type and
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7 receptors have a glycine at the position four residues past
TrpB, whereas the high affinity 44 and 42 have a lysine.
Modeling studies (53) andmutagenesis studies (15) suggest that
this structural change influences the shape of the aromatic box,
impacting agonist binding. Note, however, that although 44
and 42 show generally similar binding behaviors, 7 and
muscle-type receptors differ from one another in that ACh
binds to TrpB in the muscle-type but to TyrA in 7. As such,
other factorsmust also contribute to the shaping of the agonist-
binding site.
We have now studied four members of the nAChR family:
muscle-type, 42, 44, and 7 (Fig. 5). Here we identify
structural features of the nAChR that discriminate among these
four receptors and are likely to contribute to differential recep-
tor pharmacology. In the muscle-type receptor, TrpB makes a
cation- interaction to ACh and to epibatidine, but not to nic-
otine (12–14). In the neuronal 44 and 42 receptors, the
TrpB cation- interaction to ACh remains, but now nicotine
also makes a strong cation- interaction (15). The 7 receptor
eschews the cation- interaction to TrpB, as agonists have
moved their cationic center across the aromatic box to TyrA
and TyrC2. The nAChR family also uses a backbone hydrogen
bonding interaction as a second discriminating feature for
drug-receptor interactions. This interaction is modest in the
muscle-type and 7 receptors; it is much stronger in 44 and
42, the higher sensitivity receptors. Taken as a whole, the
data support the view that the energy of the cation- and
hydrogen bond interactions studied here underlies the higher
sensitivity of these two receptors.
Of course, these observations beg the next question as to
what features of the receptor are responsible for these changes,
remembering that the residues probed here are conserved in all
of the receptors. Further experiments are underway to probe
both the non- subunits and residues within the  subunit that
are located outside the aromatic box.
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